Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines
The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
The gradual loss of DNA from the ends of telomeres has been implicated in the control of cellular proliferative potential. Telomerase is an enzyme that restores telomeric DNA sequences, and expression of its activity was thought to be essential for the immortalization of human cells, both in vitro and in tumor progression in vivo. Telomerase activity has been detected in 50-100% of tumors of different types, but not in most normal adult somatic tissues. It has also been detected in about 70% of human cell lines immortalized in vitro and in all tumor-derived cell lines examined to date. It has previously been shown that in vitro immortalized telomerase-negative cell lines acquire very long and heterogeneous telomeres in association with immortalization presumably via one or more novel telomere-lengthening mechanisms that we refer to as ALT (alternative lengthening of telomeres). Here we report evidence for the presence of ALT in a subset of tumor-derived cell lines and tumors. The maintenance of telomeres by a mechanism other than telomerase, even in a minority of cancers, has major implications for therapeutic uses of telomerase inhibitors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“a few rare tumors (29) and some experimentally immortalized cell lines (30) lack detectable telomerase activity.”
From Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death (1999) · cites this paper as [30]
In the citing paper
“Virally transformed human cells that eliminate p53 and/or pRB function can escape crisis at very low frequencies, and invariably adopt telomere-maintenance programs: 80-90% of human tumors possess some telomerase activity, while the remainder maintain telomeres via a recombination-mediated process termed ALT (for Alternative Lengthening of Telomeres)37-40.”
From Telomere dysfunction and tumour suppression: the senescence connection (2008) · cites this paper as [39]
In the citing paper
“A significant number of human tumours can also maintain telomeres by recombination-based ALT mechanisms in the absence of telomerase 72 .”
From The common biology of cancer and ageing (2007) · cites this paper as [72]
Citations
Cites
Specific Association of Human Telomerase Activity with Immortal Cells and Cancer
Kim, N. W., Piatyszek, M. A., Prowse, K. R., Harley, C. B., West, M. D., Ho, P. L. C., Coviello, G. M., Wright, W. E., Weinrich, S. L., & Shay, J. W. (1994) · Science · doi:10.1126/science.7605428 · Cited by 7,091
Telomeres shorten during ageing of human fibroblasts
Harley, C. B., Futcher, A. B., & Greider, C. W. (1990) · Nature · doi:10.1038/345458a0 · Cited by 5,750
The p53 tumour suppressor gene
Levine, A. J., Momand, J., & Finlay, C. A. (1991) · Nature · doi:10.1038/351453a0 · Cited by 3,788
Identification of a specific telomere terminal transferase activity in tetrahymena extracts
Greider, C. W., & Blackburn, E. H. (1985) · Cell · doi:10.1016/0092-8674(85)90170-9 · Cited by 3,400
Counter, C. M., Avilion, A. A., LeFeuvre, C. E., Stewart, N. G., Greider, C. W., Harley, C. B., & Bacchetti, S. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05245.x · Cited by 2,096
Telomere reduction in human colorectal carcinoma and with ageing
Hastie, N. D., Dempster, M., Dunlop, M. G., Thompson, A. M., Green, D. K., & Allshire, R. C. (1990) · Nature · doi:10.1038/346866a0 · Cited by 1,650
Telomere elongation in immortal human cells without detectable telomerase activity
Bryan, T. M., Englezou, A., Gupta, J., Bacchetti, S., & Reddel, R. R. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb00098.x · Cited by 1,279
Self-citationTelomere loss: mitotic clock or genetic time bomb?
Harley, C. B. (1991) · Mutation Research/DNAging · doi:10.1016/0921-8734(91)90018-7 · Cited by 1,139
An alternative pathway for yeast telomere maintenance rescues est1− senescence
Lundblad, V., & Blackburn, E. H. (1993) · Cell · doi:10.1016/0092-8674(93)90234-h · Cited by 942
Telomerase activity in human ovarian carcinoma.
Counter, C. M., Hirte, H. W., Bacchetti, S., & Harley, C. B. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.8.2900 · Cited by 677
Cited by
Items 301–400 of 1,000
A practical qPCR approach to detect TERRA, the elusive telomeric repeat-containing RNA
Feretzaki, M., & Lingner, J. (2017) · Methods · doi:10.1016/j.ymeth.2016.08.004 · Cited by 82
The Response to DNA Damage at Telomeric Repeats and Its Consequences for Telomere Function
Doksani, Y. (2019) · Genes · doi:10.3390/genes10040318 · Cited by 78
High resolution long-read telomere sequencing reveals dynamic mechanisms in aging and cancer
Schmidt, T. T., Tyer, C., Rughani, P., Haggblom, C., Jones, J. R., Dai, X., Frazer, K. A., Gage, F. H., Juul, S., Hickey, S. F., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48917-7 · Cited by 94
“For example, the p arms of the human acrocentric chromosomes 13, 14, 15, 21, and 22 were shown to recombine frequently due to their homology 50 .”
InfluentialA Quantitative Assay for Telomere Protection in Saccharomyces cerevisiae
DuBois, M. L., Haimberger, Z. W., McIntosh, M. W., & Gottschling, D. E. (2002) · Genetics · doi:10.1093/genetics/161.3.995 · Cited by 82
Quantitative assessment of telomerase components in cancer cell lines
Akıncılar, S. C., Low, K. C., Liu, C. Y., Yan, T. D., Oji, A., Ikawa, M., Li, S., & Tergaonkar, V. (2015) · FEBS Letters · doi:10.1016/j.febslet.2015.02.035 · Cited by 79
“We chose U2OS and VA13 cells which have been reported to be negative for telomerase activity [37,38] by using a TRAP assay.”
MethodRole of Telomeres and Telomeric Proteins in Human Malignancies and Their Therapeutic Potential
Fernandes, S. G., Dsouza, R., Pandya, G., Kirtonia, A., Tergaonkar, V., Lee, S. Y., Garg, M., & Khattar, E. (2020) · Cancers · doi:10.3390/cancers12071901 · Cited by 87
Telomeres in Neonates: New Insights in Fetal Hematopoiesis
Friedrich, U. A., Schwab, M. G., Griese, E., Fritz, P., & Klotz, U. E. (2001) · Pediatric Research · doi:10.1203/00006450-200102000-00020 · Cited by 89
“Despite the observation that some immortalized cell lines manifest stable telomeres without evidence of telomerase activity (4), telomerase-dependent telomere elongation seems to be the most important mechanism for maintaining telomere length in vitro and in vivo.”
BackgroundBejarano, L., Schuhmacher, A. J., Méndez, M., Megías, D., Blanco‐Aparicio, C., Martínez, S., Pastor, J., Squatrito, M., & Blasco, M. A. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.10.006 · Cited by 82
“The promoter of the TERT gene is mutated in 58%–84% of human primary GBMs (Nonoguchi et al., 2013; Boldrini et al., 2006), while pediatric GBMs frequently display an ALT phenotype associated with ATRX mutations (Heaphy et al., 2011).”
BackgroundSoft Tissue Sarcoma: An Insight on Biomarkers at Molecular, Metabolic and Cellular Level
Pillozzi, S., Bernini, A., Palchetti, I., Crociani, O., Antonuzzo, L., Campanacci, D. A., & Scoccianti, G. (2021) · Cancers · doi:10.3390/cancers13123044 · Cited by 80
Telomerase-independent Regulation of ATR by Human Telomerase RNA
Kedde, M., le Sage, C., Duursma, A. M., Zlotorynski, E., van Leeuwen, B., Nijkamp, W., Beijersbergen, R. L., & Agami, R. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m607676200 · Cited by 86
DNA ends: maintenance of chromosome termini versus repair of double strand breaks
Lundblad, V. (2000) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/s0027-5107(00)00052-x · Cited by 84
RAD51AP1 Is an Essential Mediator of Alternative Lengthening of Telomeres
González, J. B., García-Expósito, L., Hoang, S. M., Lynskey, M. L., Roncaioli, J. L., Ghosh, A., Wallace, C. T., de Vitis, M., Modesti, M., Bernstein, K. A., et al. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.06.043 · Cited by 85
“However, when telomerase is suppressed, telomeres engage a homology directed repair (HDR) mechanism of telomere length maintenance termed Alternative Lengthening of Telomeres (ALT) (Bryan et al., 1997).”
BackgroundTelomere shortening and telomerase reactivation in dysplastic nodules of human hepatocarcinogenesis
Oh, B.-K., Chae, K. J., Park, C., Kim, K. S., Lee, W. J., Han, K., & Park, Y. N. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(03)00395-7 · Cited by 81
Alternative Lengthening of Telomeres in Human Glioma Stem Cells
Silvestre, D. C., Pineda, J. R., Hoffschir, F., Studler, J., Mouthon, M., Pflumio, F., Junier, M., Chneiweiss, H., & Boussin, F. D. (2011) · Stem Cells · doi:10.1002/stem.600 · Cited by 79
A human cell line that maintains telomeres in the absence of telomerase and of key markers of ALT
Cerone, M. A., Autexier, C., Londoño‐Vallejo, A., & Bacchetti, S. (2005) · Oncogene · doi:10.1038/sj.onc.1208934 · Cited by 89
“Although less frequent than telomerase, ALT has been found to maintain telomeres in at least 30–40% of immortalized human cell lines and 10–15% of human tumors (Bryan et al., 1995, 1997a; Bryan and Reddel, 1997).”
BackgroundInfluentialPotent Inhibition of Human Telomerase by Nitrostyrene Derivatives
Kim, J., Kim, J. H., Lee, G. E., Lee, J. E., & Chung, I. K. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.5.1117 · Cited by 83
“As a control for telomerase inhibitor specificity, telomerase-negative SAOS-2 cells, which exhibit the alternative lengthening of telomere phenotype (Bryan et al., 1995, 1997), were treated with DPNS for 80 PD.”
MethodMasutomi, K., & Hahn, W. C. (2003) · Cancer Letters · doi:10.1016/s0304-3835(02)00703-6 · Cited by 83
Kim, C., Kim, J., Kim, S., Cook, D. E., Evans, K. S., Andersen, E. C., & Lee, J. (2019) · Genome Research · doi:10.1101/gr.246082.118 · Cited by 79
“This ALT process uses sequences other than canonical telomeric repeats (Bryan et al. 1997; Pich and Schubert 1998; Cesare and Reddel 2010; Garavís et al. 2013; Mason et al. 2016).”
Telomere elongation chooses TERRA ALTernatives
Arora, R., & Azzalin, C. M. (2015) · RNA Biology · doi:10.1080/15476286.2015.1065374 · Cited by 73
Short Telomeres Initiate Telomere Recombination in Primary and Tumor Cells
Morrish, T. A., & Greider, C. W. (2009) · PLoS Genetics · doi:10.1371/journal.pgen.1000357 · Cited by 73
“Most human tumor cells have detectable telomerase activity, however some proliferating tumors lack telomerase and thus maintain telomeres by alternative mechanisms that are collectively termed ALT for alternative lengthening of telomeres [4,5].”
BackgroundVilla, R., Daidone, M. G., Motta, R., Venturini, L., Marco, C. D., Vannelli, A., Kusamura, S., Baratti, D., Deraco, M., Costa, A., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0099 · Cited by 79
Self-citationChang, F. T. M., Chan, F. L., R. McGhie, J. D., Udugama, M., Mayne, L., Collas, P., Mann, J. R., & Wong, L. H. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv104 · Cited by 66
DNA Repair at Telomeres: Keeping the Ends Intact
Webb, C. J., Wu, Y., & Zakian, V. A. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a012666 · Cited by 81
“As in type II ALT in budding yeast, telomere length is highly heterogeneous in human ALT. Extrachromosomal circles of telomeric DNA, known as tcircles, are associated with ALT in yeasts and mammals (Natarajan and McEachern 2002; Natarajan et al. 2003; Cesare and Griffith 2004; Wang et al. 2004).”
BackgroundInfluentialTelomere ResQue and preservation—Roles for the Werner syndrome protein and other RecQ helicases
Opresko, P. L. (2007) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2007.10.007 · Cited by 77
Multiple Mechanisms of Telomere Maintenance Exist in Liposarcomas
Johnson, J. E., Varkonyi, R. J., Schwalm, J., Cragle, R., Klein–Szanto, A. J., Patchefsky, A. S., Cukierman, E., von Mehren, M., & Broccoli, D. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0684 · Cited by 81
Folini, M., Colella, G., Villa, R., Lualdi, S., Daidone, M. G., & Zaffaroni, N. (2000) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2000.00870.x · Cited by 80
Review, part 1: Human herpesvirus‐6‐basic biology, diagnostic testing, and antiviral efficacy
Flamand, L., Komaroff, A. L., Arbuckle, J. H., Medveczky, P. G., & Ablashi, D. V. (2010) · Journal of Medical Virology · doi:10.1002/jmv.21839 · Cited by 71
“However, in those remaining cells it is expected that telomere length is maintained through alternative lengthening of telomeres (ALT) [Bryan et al., 1997].”
BackgroundFunctions of BLM Helicase in Cells: Is It Acting Like a Double-Edged Sword?
Kaur, E., Agrawal, R., & Sengupta, S. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.634789 · Cited by 74
“ALTERATIONS IN BLM LEVELS BS is caused by either homozygous or compound heterozygous mutations in the BLM gene located at the 15q26.”
BackgroundInfluentialHwang, H. H., Kreig, A., Calvert, J. S., Lormand, J. D., Kwon, Y., Daley, J. M., Sung, P., Opresko, P. L., & Myong, S. (2014) · Structure · doi:10.1016/j.str.2014.03.013 · Cited by 78
“Many factors likely contribute to the regulation of telomere lengthening by ALT or telomerase, and our data provide evidence that telomere overhang length is one factor that may contribute to this regulation.”
BackgroundInfluentialTelomere-driven genomic instability in cancer cells
Desmaze, C., Soria, J., Freulet-Marrière, M.-A., Mathieu, N., & Sabatier, L. (2003) · Cancer Letters · doi:10.1016/s0304-3835(02)00704-8 · Cited by 80
Telomerase activity in melanoma and non-melanoma skin cancer
Parris, C. N., Jezzard, S., Silver, A. R., Mackie, R. M., McGregor, J. M., & Newbold, R. F. (1998) · British Journal of Cancer · doi:10.1038/sj.bjc.6690010 · Cited by 75
“ka rin In th bou an ea 20 95 ivi the iliz c be ei ica ma leo re vo G re rin, tion y has hose and ivity ch as et al, and ). ere is aetiskin ctivanonf the ment ation nt of een been tion tabillular ngly e for erall, skin Telomerase activity in melanoma and non-melanoma skin cancer”
BackgroundOpportunities and challenges of targeting cGAS–STING in cancer
Lu, C., Wang, W., & Fu, Y. (2026) · Nature reviews. Cancer · doi:10.1038/s41568-025-00894-9 · Cited by 79
Telomere regulation in pluripotent stem cells
Huang, Y. Y., Liang, P., Liu, D., Huang, J., & Songyang, Z. (2014) · Protein & Cell · doi:10.1007/s13238-014-0028-1 · Cited by 77
“While 85%–90% of human cancers extend telomeres through the upregulation of telomerase activity, 10%–15% of cancers use the ALT pathway, a process that appears dependent on homologous recombination (Bryan et al., 1997; Shay and Bacchetti, 1997).”
BackgroundHomologous recombination in human telomerase‐positive and ALT cells occurs with the same frequency
Bechter, O. E., Zou, Y. S., Shay, J. W., & Wright, W. E. (2003) · EMBO Reports · doi:10.1038/sj.embor.7400027 · Cited by 83
“Approximately 25% of all in vitro simian virus 40 (SV40) large T-antigen immortalized human fibroblast cell lines use the ALT pathway while it is found in about 7% of tumour-derived cell lines or human tumour samples (Bryan et al., 1997).”
BackgroundTelomeres and the DNA damage response: why the fox is guarding the henhouse
Maser, R. S., & DePinho, R. A. (2004) · DNA repair · doi:10.1016/j.dnarep.2004.05.009 · Cited by 82
Tomáška, Ľ., Nosek, J., Makhov, A. M., Pastorakova, A., & Griffith, J. D. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.22.4479 · Cited by 73
Telomeres and chromosomal instability
Mathieu, N., Pirzio, L. M., Freulet-Marrière, M.-A., Desmaze, C., & Sabatier, L. (2004) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-003-3296-0 · Cited by 77
Telomerase: a therapeutic target for the third millennium?
Lavelle, F., Riou, J., Laoui, A., & Mailliet, P. (2000) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(00)00057-3 · Cited by 74
Telomeres, telomerase, and apoptosis
Mondello, C., & Scovassi, A. I. (2004) · Biochemistry and Cell Biology · doi:10.1139/o04-048 · Cited by 73
“Up to 10% of human tumor cells that lack detectable telomerase activity are able to maintain the length of their telomeres with ALT (alternative lengthening of telomeres), a telomerase-independent mechanism that may be mediated by recombination (Bryan et al. 1997; Dunham et al. 2000).”
BackgroundTelomerase Activity in Human Gliomas
Le, S., Zhu, J., Anthony, D. C., Greider, C. W., & Black, P. M. (1998) · Neurosurgery · doi:10.1097/00006123-199805000-00099 · Cited by 68
Sumoylation of RecQ Helicase Controls the Fate of Dysfunctional Telomeres
Rog, O., Miller, K. M., Ferreira, M. G., & Cooper, J. P. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.01.027 · Cited by 70
“In mammalian cells proliferating without telomerase through activation of the ALT pathway, telomeres localize to PML bodies in the nucleus, where their elongation presumably occurs via recombination (Bryan et al., 1997).”
BackgroundImplications of TERT promoter mutations and telomerase activity in urothelial carcinogenesis
Güneş, Ç., Wezel, F., Southgate, J., & Bolenz, C. (2018) · Nature Reviews Urology · doi:10.1038/s41585-018-0001-5 · Cited by 73
Simon, M., Park, T., Leuenroth, S., Hans, V., Löning, T., & Schramm, J. (2000) · Journal of neurosurgery · doi:10.3171/jns.2000.92.5.0832 · Cited by 71
Telomere maintenance mechanisms as a target for drug development
Bearss, D. J., Hurley, L. H., & Hoff, D. D. V. (2000) · Oncogene · doi:10.1038/sj.onc.1204092 · Cited by 76
“However, it is of note that most carcinoma-derived cell lines utilize upregulation of telomerase rather than an alternative mechanism of lengthening telomeres (Bryan et al., 1997; Colgin and Reddel, 1999).”
BackgroundLiu, L., Saldanha, S. N., Pate, M. S., Andrews, L. G., & Tollefsbol, T. O. (2004) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.20058 · Cited by 65
“Alternative mechanisms of maintaining telomere length have been reported in both mouse and human cells (Bryan et al., 1997; Jaco et al., 2003), but most tumors examined so far appear to employ telomerase activation as a means of escaping senescence and retaining a high proliferative potential.”
BackgroundTelomerase activity distinguishes between neuroblastomas with poor prognosis
Poremba, C., Willenbring, H., Hero, B., Christiansen, H., Schäfer, K.-L., Brinkschmidt, C., Jürgens, H., Böcker, W., & Dockhorn‐Dworniczak, B. (1999) · Annals of Oncology · doi:10.1023/a:1008333500733 · Cited by 77
Fathi, E., Valipour, B., Sanaat, Z., Charoudeh, H. N., & Farahzadi, R. (2020) · Advanced Pharmaceutical Bulletin · doi:10.34172/apb.2020.037 · Cited by 88
Assembly of telomeric chromatin to create ALTernative endings
O’Sullivan, R. J., & Almouzni, G. (2014) · Trends in Cell Biology · doi:10.1016/j.tcb.2014.07.007 · Cited by 72
Alonso, M. M., Fueyo-Margareto, J., Shay, J. W., Aldape, K., Jiang, H., Lee, O.-H., Johnson, D. G., Xu, J., Kondo, Y., Kanzawa, T., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji340 · Cited by 66
Telomeres, telomerase, and tumorigenesis--a review.
Lin, K. W. (2004) · PubMed · Cited by 89
Telomere Length Maintenance, Shortening, and Lengthening
Zhao, Z., Pan, X., Liu, L., & Liu, N. (2014) · Journal of Cellular Physiology · doi:10.1002/jcp.24537 · Cited by 66
“In addition, alternative mechanism (ALT) can maintain telomere length (Bryan et al., 1997).”
BackgroundPennaneach, V., & Kolodner, R. D. (2004) · Nature Genetics · doi:10.1038/ng1359 · Cited by 71
“or through the alternative lengthening of telomere pathwa”
BackgroundComparative analysis of whole genome sequencing-based telomere length measurement techniques
Lee, M., Napier, C. E., Yang, S. F., Arthur, J. W., Reddel, R. R., & Pickett, H. A. (2016) · Methods · doi:10.1016/j.ymeth.2016.08.008 · Cited by 72
Self-citationChromosome instability in neoplasia: chaotic roots to continuous growth
Gagos, S., & Irminger‐Finger, I. (2005) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2005.01.003 · Cited by 78
Modeling chromosomal instability and epithelial carcinogenesis in the telomerase-deficient mouse
Chang, S. S., Khoo, C., & DePinho, R. A. (2001) · Seminars in Cancer Biology · doi:10.1006/scbi.2000.0374 · Cited by 72
Telomere Length and Pancreatic Cancer: A Case–Control Study
Skinner, H. G., Gangnon, R. E., Litzelman, K., Johnson, R., Chari, S. T., Petersen, G. M., & Boardman, L. A. (2012) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-12-0671 · Cited by 64
Sishc, B. J., Nelson, C. B., McKenna, M. J., Battaglia, C. L. R., Herndon, A. K., Idate, R., Liber, H. L., & Bailey, S. M. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00257 · Cited by 70
“The overwhelming majority of human cancers (~90%) accomplish this task by the way of reactivation of telomerase (14); the remaining ~10% of cancers maintain telomere length in a telomerase-independent fashion, relying instead on the homologous recombination (HR)-associated alternative lengthening of telomeres (ALT) pa…”
BackgroundGhaffari, S. H., Shayan-Asl, N., Jamialahmadi, H., Alimoghaddam, K., & Ghavamzadeh, A. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn394 · Cited by 62
“The stabilized telomeres, by telomerase or some times by an alternative mechanism called alternative lengthening of telomere [3], confer cell immortalization and have the ability to proliferate indefinitely.”
BackgroundTelomere dynamics in genome stability
Bhattacharyya, M. K., & Lustig, A. J. (2006) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2005.12.001 · Cited by 71
Tilman, G., Loriot, A. E., Beneden, A. V., Arnoult, N., Londoño‐Vallejo, A., Smet, C. D., & Decottignies, A. (2009) · Oncogene · doi:10.1038/onc.2009.23 · Cited by 62
“A subset of tumors and about 50% of SV40-immortalized cell lines maintain their telomeres by one or more telomeraseindependent mechanisms referred to as alternative lengthening of telomeres (ALT) (Bryan et al., 1997).”
BackgroundTelomere dynamics: the influence of folate and DNA methylation
Moores, C. J., Fenech, M. F., & O’Callaghan, N. J. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.06101.x · Cited by 65
Telomeric armor: the layers of end protection
Oganesian, L., & Karlseder, J. (2009) · Journal of Cell Science · doi:10.1242/jcs.050567 · Cited by 66
“To what extent is telomere protection tampered with in immortalized cells that have activated telomeremaintenance pathways [namely alternative lengthening of telomeres (ALT)] (Bryan et al., 1997) or the pathway mediated by the ribonucleoprotein enzyme telomerase (Greider and Blackburn, 1985)?”
BackgroundKamranvar, S. A., Chen, X., & Masucci, M. G. (2013) · Oncogene · doi:10.1038/onc.2013.189 · Cited by 63
Regulation of Telomerase Alternative Splicing: A Target for Chemotherapy
Wong, M. S., Chen, L., Foster, C., Kainthla, R., Shay, J. W., & Wright, W. E. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.03.011 · Cited by 69
“A recombination-based mechanism named alternative lengthening of telomeres (ALT) is used to maintain telomeres in some telomerase-negative tumors (Bryan et al., 1997).”
Alternative lengthening of telomeres can be maintained by preferential elongation of lagging strands
Min, J., Wright, W. E., & Shay, J. W. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1295 · Cited by 75
“ALT is a telomerase-independent telomere maintenance mechanism that occurs in a small subset of cancers (8).”
Telomerase extracurricular activities
Chang, S., & DePinho, R. A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.212514699 · Cited by 60
Goodwin, E. C., & DiMaio, D. (2001) · PubMed · Cited by 66
Wen, J., Cong, Y.-S., & Bacchetti, S. (1998) · Human Molecular Genetics · doi:10.1093/hmg/7.7.1137 · Cited by 61
Telomere function and regulation from mouse models to human ageing and disease
Jones-Weinert, C. W., Mainz, L., & Karlseder, J. (2024) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-024-00800-5 · Cited by 70
“How caPOT1 mutations lead to telomere elongation is not yet clear, but it has been speculated that, in the absence of telomerase, these loss of function mutations increase telomere instability and facilitate ALT activation 278 .”
InfluentialRequirement of DDX39 DEAD box RNA helicase for genome integrity and telomere protection
Yoo, H. H., & Chung, I. K. (2011) · Aging Cell · doi:10.1111/j.1474-9726.2011.00696.x · Cited by 68
“Although recombinationmediated telomere elongation has been demonstrated for replenishing telomeric DNA (Bryan et al., 1997; Dunham et al., 2000), the major mechanism to counteract telomere erosion is based on telomerase (Autexier & Lue, 2006; Bianchi & Shore, 2008).”
BackgroundTelomere dysfunction and its role in haematological cancer
Jones, C. H., Pepper, C. J., & Baird, D. M. (2012) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.09022.x · Cited by 67
“ALT has been in observed primarily in tumours of mesenchymal origin; however, currently there is no evidence of ALT in haematological malignancies (Bryan et al, 1997).”
BackgroundMYC drives overexpression of telomerase RNA ( hTR / TERC ) in prostate cancer
Valle, J. A. B.-D., Zheng, Q., Esopi, D., Rubenstein, M., Hubbard, G. K., Moncaliano, M. C., Hruszkewycz, A. M., Vaghasia, A. M., Yegnasubramanian, S., Wheelan, S. J., et al. (2017) · The Journal of Pathology · doi:10.1002/path.4980 · Cited by 66
“As a negative control, we used U-2 OS cells, which are known to be negative for TA and TERC expression [26,42] and which we verified by RT-qPCR.”
MethodTsai, Y.-L., Tseng, S., Chang, S.-H., Lin, C., & Teng, S. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.16.5679-5687.2002 · Cited by 68
“It seems that at least two steps are involved in type II and ALT survival.”
BackgroundInfluentialPeška, V., Fajkus, P., Fojtová, M., Dvořáčková, M., Hapala, J., Dvořáček, V., Polanská, P., Leitch, A. R., Sýkorová, E., & Fajkus, J. (2015) · The Plant Journal · doi:10.1111/tpj.12839 · Cited by 66
Subhawong, A. P., Heaphy, C. M., Argani, P., Konishi, Y., Kouprina, N., Nassar, H., VANG, R. S., & Meeker, A. K. (2009) · Modern Pathology · doi:10.1038/modpathol.2009.125 · Cited by 66
Telomeres in Plants and Humans: Not So Different, Not So Similar
Schrumpfová, P. P., Fojtová, M., & Fajkus, J. (2019) · Cells · doi:10.3390/cells8010058 · Cited by 62
“Besides telomerase, eukaryotic cells can also utilize a back-up mechanism of telomere maintenance—ALT—which is based on homologous recombination (HR) [236].”
BackgroundVaziri, H., & Benchimol, S. (1999) · Oncogene · doi:10.1038/sj.onc.1203016 · Cited by 68
“Emergence of immortal, telomerase-negative cells both in vitro (Bryan et al., 1995) and in vivo (Bryan et al., 1997) attest to this possibility.”
BackgroundIn Vitro Expansion of Human Hepatocytes is Restricted by Telomere-Dependent Replicative Aging
Wege, H., Chui, M. S., Le, H. T., Strom, S. C., & Zern, M. Α. (2003) · Cell Transplantation · doi:10.3727/000000003771000138 · Cited by 65
Improved detection and comparative sizing of human chromosomal telomeres in situ
Krejčí, K., & Koch, J. (1998) · Chromosoma · doi:10.1007/s004120050297 · Cited by 58
“More likely it reflects a non-telomerase-based mechanism as has been recently reported for a number of tumors (Bryan et al. 1997).”
BackgroundGarcía‐Beccaria, M., Martínez, P., Méndez‐Pertuz, M., Martínez, S., Blanco‐Aparicio, C., Cañamero, M., Mulero, F., Ambrogio, C., Flores, J. M., Megias, D., et al. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201404497 · Cited by 55
“…telomere length, 80 – 90% of human tumors reactivate telomerase (Kim et al , 1994; Shay & Bacchetti, 1997; Joseph et al , 2010), and the remaining activate an alternative mechanism to maintain telomeres, known as ALT, based on recombination between telomeric sequences (Bryan et al , 1997).”
The potential utility of telomere‐related markers for cancer diagnosis
Heaphy, C. M., & Meeker, A. K. (2011) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2011.01284.x · Cited by 57
“The ALT phenotype [45] has been primarily observed in sarcomas, but is relatively rare in most carcinomas [47].”
BackgroundTelomere length variation in biliary tract metaplasia, dysplasia, and carcinoma
Hansel, D. E., Meeker, A. K., Hicks, J. L., Marzo, A. M. D., Lillemoe, K. D., Schulick, R. D., Hruban, R. H., Maitra, A., & Argani, P. (2006) · Modern Pathology · doi:10.1038/modpathol.3800591 · Cited by 61
“These findings may be accounted for by varying rates of telomere shortening in individual cells, possible variable reactivation of telomerase within subpopulations of neoplastic cells, or utilization of the alternative lengthening telomeres pathway in a subset of biliary carcinomas”
BackgroundMechanisms that drive telomere maintenance and recombination in human cancers
Sobinoff, A. P., & Pickett, H. A. (2020) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2020.02.006 · Cited by 59
Tolstonog, G. V., Shoeman, R. L., Traub, U., & Traub, P. (2001) · DNA and Cell Biology · doi:10.1089/104454901317094945 · Cited by 60
Hashimoto, Y., Murakami, Y., Uemura, K., Hayashidani, Y., Sudo, T., Ohge, H., Fukuda, E., Shimamoto, F., Sueda, T., & Hiyama, E. (2007) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-007-0383-9 · Cited by 59
Measurement of Telomerase Activity in Dog Tumors
Yazawa, M., Okuda, M., Setoguchi, A., Nishimura, R., Sasaki, N., Hasegawa, A., WATARI, & Tsujimoto, H. (1999) · Journal of Veterinary Medical Science · doi:10.1292/jvms.61.1125 · Cited by 59
“Although the telomerase activities were undetectable or low in these tumors, they might have telomerase-independent mechanisms for maintaining the length of telomeres as shown in some human tumors and cell lines [8].”
BackgroundInhibition of Telomerase Recruitment and Cancer Cell Death
Nakashima, M., Nandakumar, J., Sullivan, K. D., Espinosa, J. M., & Cech, T. R. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.518175 · Cited by 59
Molecular Markers in Low-Grade Glioma—Toward Tumor Reclassification
Olar, A., & Sulman, E. P. (2015) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2015.02.006 · Cited by 66
Chavez, A., George, V., Agrawal, V., & Johnson, F. B. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.041277 · Cited by 62
Sasaki, T., Tazawa, H., Hasei, J., Kunisada, T., Yoshida, A., Hashimoto, Y., Yano, S., Yoshida, R., Uno, F., Kagawa, S., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2066 · Cited by 62
“Recently, some populations of human sarcoma cells have been shown to possess low telomerase activity and to maintain telomere lengths through an ALT mechanism (17-19).”
BackgroundHighly Aggressive Metastatic Melanoma Cells Unable to Maintain Telomere Length
Viceconte, N., Dheur, M.-S., Majerová, E., Pierreux, C. E., Baurain, J., van Baren, N., & Decottignies, A. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.05.046 · Cited by 54
Multiple cancer pathways regulate telomere protection
Bejarano, L., Bosso, G., Louzame, J., Serrano, R., Gómez‐Casero, E., Martinez-Torrecuadrada, J. L., Martínez, S., Blanco‐Aparicio, C., Pastor, J., & Blasco, M. A. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201910292 · Cited by 58
“The majority of cancer cells aberrantly activate telomerase or ALT mechanisms to be able to divide indefinitely (Kim et al, 1994; Bryan et al, 1995; Shay & Bacchetti, 1997; Barthel et al, 2017).”
BackgroundInfluentialPML Nuclear Body Biogenesis, Carcinogenesis, and Targeted Therapy
Li, Y., Ma, X., Wu, W., Zhu, C., & Meng, G. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.05.005 · Cited by 56
Telomerase activity in plasma cell dyscrasias
Xu, D., Zheng, C., Bergenbrant, S., Holm, G., Björkholm, M., Yi, Q., & Gruber, A. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2000.1655 · Cited by 58
Moróte, J., de Torres, I. M., Càceres, C., Vallejo, C. T., Schwartz, S., & Reventós, J. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990820)84:4<339::aid-ijc1>3.0.co;2-2 · Cited by 84
Dynamic rearrangement of telomeres during spermatogenesis in mice
Tanemura, K., Ogura, A., Cheong, C., Gotoh, H., Matsumoto, K., Sato, E., Hayashi, Y., Lee, H., & Kondo, T. (2005) · Developmental Biology · doi:10.1016/j.ydbio.2005.02.025 · Cited by 62
“The observation that telomere extension activity is preserved during germ cell production, even in the absence of the telomerase complex, strongly suggests the existence of alternative telomere synthetic pathway(s) (Bryan et al., 1997; Dunham et al., 2000; Niida et al., 2000; Reddel, 2003) and the importance of telome…”
BackgroundRegulation of telomere length in Drosophila
Frydrychová, R. Č., Biessmann, H., & Mason, J. M. (2008) · Cytogenetic and Genome Research · doi:10.1159/000167823 · Cited by 62
“…those using telomerase, telomere-specific retrotransposons have been observed in Drosophila (Mason and Biessmann, 1995), and alternative lengthening of telomeres (Bryan et al., 1995, 1997) by recombination has been found in many sarcomas that do not express telomerase (Henson et al., 2005).”
BackgroundBender, H. S., Murchison, E. P., Pickett, H. A., Deakin, J. E., Strong, M. A., Conlan, C., McMillan, D. A., Neumann, A. A., Greider, C. W., Hannon, G. J., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046195 · Cited by 60
“In contrast, ALT-positive cancer cells are typified by strikingly heterogeneous telomeres and the presence of ALT-associated promyelocytic leukemia protein nuclear bodies (APBs) [13].”
InfluentialSelf-citationTelomerase-based Cancer Therapeutics: A Review on their Clinical Trials
Relitti, N., Saraswati, A. P., Federico, S., Khan, T., Brindisi, M., Zisterer, D. M., Brogi, S., Gemma, S., Butini, S., & Campiani, G. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200102104930 · Cited by 56
Neural stem cells in aging and disease
Limke, T. L., & Rao, M. S. (2002) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2002.tb00451.x · Cited by 54
Metadata
- Authors
- Bryan, T. M., Englezou, A., Dalla-Pozza, L., Dunham, M. A., & Reddel, R. R.
- Affiliations
- Children's Medical Research Institute (AU)
- Corresponding author
- Reddel, Roger R.
- Venue
- Nature Medicine
- Published
- 1997-11
- Volume
- 3
- Issue
- 11
- Pages
- 1271-1274
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2013073993
- Cited by
- 1,292
- References
- 39
- Citations by year
- 2026: 19 · 2025: 41 · 2024: 37 · 2023: 48 · 2022: 31 · 2021: 34 · 2020: 44 · 2019: 52 · 2018: 27 · 2017: 54 · 2016: 35 · 2015: 52 · 2014: 33 · 2013: 52 · 2012: 39
- FWCI
- 27.26
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA and Nucleic Acid Chemistry
- Keywords
- alternative lengthening of telomeres, telomere maintenance, telomerase, tumor-derived cell lines, cell immortalization, telomerase inhibitors, cancer therapy, telomere loss
- MeSH terms
- Adult, DNA Nucleotidyltransferases, Humans, Neoplasms, Tumor Cells, Cultured, Deoxyribonucleases, Type II Site-Specific, Telomere, Telomerase
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.